Human TSH receptor ligands as pharmacological probes with potential clinical application

References

• Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev.13, 596–611 (1992).
   PubMed Web of Science ®Google Scholar
• Dohan O, Carrasco N. Thyroidal iodide transport and thyroid cancer. Cancer Treat. Res.122, 221–236 (2004).
   Google Scholar
• Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid18(5), 509–516 (2008).
   PubMed Web of Science ®Google Scholar
• Albino CC, Mesa CO Jr, Olandoski M et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J. Clin. Endocrinol. Metab.90(5), 2775–2780 (2005).
   PubMed Web of Science ®Google Scholar
• Bassett JH, Williams GR. Critical role of the hypothalamic–pituitary–thyroid axis in bone. Bone43(3), 418–426 (2008).
   Google Scholar
• Abe E, Marians RC, Yu W et al. TSH is a negative regulator of skeletal remodeling. Cell115(2), 151–162 (2003).
   PubMed Web of Science ®Google Scholar
• Sampath TK, Simic P, Sendak R et al. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J. Bone Miner. Res.22(6), 849–859 (2007).
   PubMed Web of Science ®Google Scholar
• Marians RC, Ng L, Blair HC, Unger P, Graves PN, Davies TF. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc. Natl Acad. Sci. USA99(24), 15776–15781 (2002).
   PubMed Web of Science ®Google Scholar
• Hase H, Ando T, Eldeiry L et al. TNFα mediates the skeletal effects of thyroid-stimulating hormone. Proc. Natl Acad. Sci. USA103(34), 12849–12854 (2006).
   Google Scholar
• Sun L, Vukicevic S, Baliram R et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc. Natl Acad. Sci. USA105(11), 4289–4294 (2008).
   PubMed Web of Science ®Google Scholar
• Bassett JH, Williams AJ, Murphy E et al. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol. Endocrinol.22(2), 501–512 (2008).
   Google Scholar
• Inoue M, Tawata M, Yokomori N, Endo T, Onaya T. Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells. Thyroid8(11), 1059–1064 (1998).
   Google Scholar
• Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J. Clin. Invest.115(8), 1972–1983 (2005).
   PubMed Web of Science ®Google Scholar
• Duprez L, Parma J, Van Sande J et al. TSH receptor mutations and thyroid disease. Trends Endocrinol. Metab.9(4), 133–140 (1998).
   Google Scholar
• Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am. J. Ophthalmol.142(1), 147–153 (2006).
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Prummel MF. Graves’ ophthalmopathy: a rational approach to treatment. Trends Endocrinol. Metab.13(7), 280–287 (2002).
   PubMed Web of Science ®Google Scholar
• Valyasevi RW, Erickson DZ, Harteneck DA et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab.84(7), 2557–2562 (1999).
   PubMed Web of Science ®Google Scholar
• Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab.83(3), 998–1002 (1998).
   PubMed Web of Science ®Google Scholar
• Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure–function relationships. Physiol. Rev.82(2), 473–502 (2002).
   PubMed Web of Science ®Google Scholar
• Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol. Metab. Clin. North Am.38(2), 319–341 (2009).
   PubMed Web of Science ®Google Scholar
• Loosfelt H, Pichon C, Jolivet A et al. Two-subunit structure of the human thyrotropin receptor. Proc. Natl Acad. Sci. USA89, 3765–3769 (1992).
   Google Scholar
• Chazenbalk GD, Tanaka K, Nagayama Y et al. Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites. Endocrinology138(7), 2893–2899 (1997).
   Google Scholar
• de Bernard S, Misrahi M, Huet JC et al. Sequential cleavage and excision of a segment of the thyrotropin receptor ectodomain. J. Biol. Chem.274(1), 101–107 (1999).
   PubMedGoogle Scholar
• Rapoport B, McLachlan SM. The thyrotropin receptor in Graves’ disease. Thyroid17(10), 911–922 (2007).
   Google Scholar
• Laugwitz KL, Allgeier A, Offermanns S et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc. Natl Acad. Sci. USA93(1), 116–120 (1996).
   PubMed Web of Science ®Google Scholar
• Kero J, Ahmed K, Wettschureck N et al. Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development. J. Clin. Invest.117(9), 2399–2407 (2007).
   Google Scholar
• Buch TR, Biebermann H, Kalwa H et al. G13-dependent activation of MAPK by thyrotropin. J. Biol. Chem.283(29), 20330–20341 (2008).
   Google Scholar
• Vlaeminck-Guillem V, Ho SC, Rodien P, Vassart G, Costagliola S. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol. Endocrinol.16(4), 736–746 (2002).
   PubMedGoogle Scholar
• Zhang M, Tong KPT, Fremont V et al. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology141(9), 3514–3517 (2000)
   PubMedGoogle Scholar
• Nakabayashi K, Matsumi H, Bhalla A et al. Thyrostimulin, a heterodimer of two new human glycoprotein hormone subunits, activates the thyroid-stimulating hormone receptor. J. Clin. Invest.109(11), 1445–1452 (2002).
   PubMed Web of Science ®Google Scholar
• Okada SL, Ellsworth JL, Durnam DM et al. A glycoprotein hormone expressed in corticotrophs exhibits unique binding properties on thyroid-stimulating hormone receptor. Mol. Endocrinol.20(2), 414–425 (2006).
   Google Scholar
• Cole ES, Lee K, Lauziere K et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology11(9), 1014–1024 (1993).
   PubMed Web of Science ®Google Scholar
• Szkudlinski MW, Thotakura NR, Bucci I et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology133(4), 1490–1503 (1993).
   PubMed Web of Science ®Google Scholar
• Szkudlinski MW. Recombinant human thyrotropins of the twenty-first century. Expert Opin. Pharmacother.5(12), 2435–2440 (2004).
   PubMed Web of Science ®Google Scholar
• Boretti FS, Sieber-Ruckstuhl NS, Favrot C, Lutz H, Hofmann-Lehmann R, Reusch CE. Evaluation of recombinant human thyroid-stimulating hormone to test thyroid function in dogs suspected of having hypothyroidism. Am. J. Vet. Res.67(12), 2012–2016 (2006).
   PubMed Web of Science ®Google Scholar
• Daminet S, Fifle L, Paradis M, Duchateau L, Moreau M. Use of recombinant human thyroid-stimulating hormone for thyrotropin stimulation test in healthy, hypothyroid and euthyroid sick dogs. Can. Vet. J.48(12), 1273–1279 (2007).
   PubMed Web of Science ®Google Scholar
• Colzani RM, Alex S, Fang SL, Braverman LE, Emerson CH. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid8(9), 797–801 (1998).
   Google Scholar
• Szkudlinski MW, Grossmann M, Weintraub BD. Structure–function studies of human TSH – new advances in design of glycoprotein hormone analogs. Trends Endocrinol. Metab.7(8), 277–286 (1996).
   Google Scholar
• Grossmann M, Wong R, Szkudlinski MW, Weintraub BD. Human thyroid-stimulating hormone (hTSH) subunit gene fusion produces hTSH with increased stability and serum half-life and compensates for mutagenesis-induced defects in subunit association. J. Biol. Chem.272(34), 21312–21316 (1997).
   Google Scholar
• Fares FA, Yamabe S, Ben Menahem D, Pixley M, Hsueh AJ, Boime I. Conversion of thyrotropin heterodimer to a biologically active single-chain. Endocrinology139(5), 2459–2464 (1998).
   Google Scholar
• Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu. Rev. Biochem.50, 465–495 (1981).
   PubMed Web of Science ®Google Scholar
• Fares FA, Levi F, Reznick AZ, Kraiem Z. Engineering a potential antagonist of human thyrotropin and thyroid-stimulating antibody. J. Biol. Chem.276(7), 4543–4548 (2001).
   Google Scholar
• Azzam N, Bar-Shalom R, Kraiem Z, Fares F. Human thyrotropin (TSH) variants designed by site-directed mutagenesis block TSH activity in vitro and in vivo. Endocrinology146(6), 2845–2850 (2005).
   Google Scholar
• Szkudlinski MW, Teh NG, Grossmann M, Tropea JE, Weintraub BD. Engineering human glycoprotein hormone superactive analogues. Bio. Technol.14(10), 1257–1263 (1996).
   Google Scholar
• Grossmann M, Leitolf H, Weintraub BD, Szkudlinski MW. A rational design strategy for protein hormone superagonists. Nat. Biotechnol.16(9), 871–875 (1998).
   PubMedGoogle Scholar
• Leitolf H, Tong KP, Grossmann M, Weintraub BD, Szkudlinski MW. Bioengineering of human thyrotropin superactive analogs by site-directed ‘lysine-scanning’ mutagenesis. Cooperative effects between peripheral loops. J. Biol. Chem.275(35), 27457–27465 (2000).
   Google Scholar
• Mueller S, Kleinau G, Szkudlinski MW, Jaeschke H, Krause G, Paschke R. The superagonistic activity of bovine TSH and the human TR1401 TSH analog is determined by specific amino acids in the hinge region of the human TSH-receptor. J. Biol. Chem.284(24), 16317–16324 (2009).
   Google Scholar
• Schott M, Scherbaum WA, Morgenthaler NG. Thyrotropin receptor autoantibodies in Graves’ disease. Trends Endocrinol. Metab.16(5), 243–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rees SB, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr. Rev.9(1), 106–121 (1988).
   PubMed Web of Science ®Google Scholar
• Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies TF. A monoclonal thyroid-stimulating antibody. J. Clin. Invest.110(11), 1667–1674 (2002).
   PubMed Web of Science ®Google Scholar
• Sanders J, Allen F, Jeffreys J et al. Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist. Thyroid15(7), 672–682 (2005).
   PubMed Web of Science ®Google Scholar
• Sanders J, Jeffreys J, Depraetere H et al. Thyroid-stimulating monoclonal antibodies. Thyroid12(12), 1043–1050 (2002).
   PubMed Web of Science ®Google Scholar
• Costagliola S, Franssen JD, Bonomi M et al. Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. Biochem. Biophys. Res. Commun.299(5), 891–896 (2002).
   PubMed Web of Science ®Google Scholar
• Huang GC, Page MJ, Nicholson LB, Collison KS, McGregor AM, Banga JP. The thyrotrophin hormone receptor of Graves’ disease: overexpression of the extracellular domain in insect cells using recombinant baculovirus, immunoaffinity purification and analysis of autoantibody binding. J. Mol. Endocrinol.10(2), 127–142 (1993).
   PubMed Web of Science ®Google Scholar
• Johnstone AP, Cridland JC, DaCosta CR, Harfst E, Shepherd PS. Monoclonal antibodies that recognize the native human thyrotropin receptor. Mol. Cell. Endocrinol.105(2), R1–R9 (1994).
   Google Scholar
• Seetharamaiah GS, Wagle NM, Morris JC, Prabhakar BS. Generation and characterization of monoclonal antibodies to the human thyrotropin (TSH) receptor: antibodies can bind to discrete conformational or linear epitopes and block TSH binding. Endocrinology136(7), 2817–2824 (1995).
   PubMed Web of Science ®Google Scholar
• Costagliola S, Rodien P, Many MC, Ludgate M, Vassart G. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J. Immunol.160(3), 1458–1465 (1998).
   PubMed Web of Science ®Google Scholar
• Oda Y, Sanders J, Evans M et al. Epitope analysis of the human thyrotropin (TSH) receptor using monoclonal antibodies. Thyroid10(12), 1051–1059 (2000).
   PubMedGoogle Scholar
• Gilbert JA, Gianoukakis AG, Salehi S et al. Monoclonal pathogenic antibodies to the thyroid-stimulating hormone receptor in Graves’ disease with potent thyroid-stimulating activity but differential blocking activity activate multiple signaling pathways. J. Immunol.176(8), 5084–5092 (2006).
   Google Scholar
• Costagliola S, Bonomi M, Morgenthaler NG et al. Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Mol. Endocrinol.18(12), 3020–3034 (2004).
   PubMedGoogle Scholar
• Akamizu T, Moriyama K, Miura M, Saijo M, Matsuda F, Nakao K. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves’ disease: epitope and binding study of two stimulatory TSHRAbs. Endocrinology140(4), 1594–1601 (1999).
   PubMed Web of Science ®Google Scholar
• Sanders J, Evans M, Premawardhana LD et al. Human monoclonal thyroid stimulating autoantibody. Lancet362(9378), 126–128 (2003).
   PubMedGoogle Scholar
• Moriyama K, Okuda J, Saijo M et al. Recombinant monoclonal thyrotropin-stimulation blocking antibody (TSBAb) established from peripheral lymphocytes of a hypothyroid patient with primary myxedema. J. Endocrinol. Invest.26(11), 1076–1080 (2003).
   Google Scholar
• Chen CR, McLachlan SM, Rapoport B. Suppression of thyrotropin receptor constitutive activity by a monoclonal antibody with inverse agonist activity. Endocrinology148(5), 2375–2382 (2007).
   PubMed Web of Science ®Google Scholar
• Sanders J, Evans M, Betterle C et al. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity. Thyroid18(7), 735–746 (2008).
   PubMed Web of Science ®Google Scholar
• Bond RA, IJzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci.27(2), 92–96 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CR, McLachlan SM, Rapoport B. Identification of key amino acid residues in a thyrotropin receptor monoclonal antibody epitope provides insight into its inverse agonist and antagonist properties. Endocrinology149(7), 3427–3434 (2008).
   Google Scholar
• Chen CR, McLachlan SM, Rapoport B. A monoclonal antibody with TSH receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain. Endocrinology150(7), 3401–3408 (2009).
   PubMed Web of Science ®Google Scholar
• Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol. Metab. Clin. North Am.38(2), 319–341 viii (2009).
   PubMed Web of Science ®Google Scholar
• Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun. Rev. DOI:10.1016/j.autrev.2009.03.012 (2009) (Epub ahead of print).
   Google Scholar
• van Straten NC, Schoonus-Gerritsma GG, van Someren RG et al. The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. Chembiochem.3(10), 1023–1026 (2002).
   Google Scholar
• Heitman LH, Oosterom J, Bonger KM, Timmers CM, Wiegerinck PH, IJzerman AP. [3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor. Mol. Pharmacol.73(2), 518–524 (2008).
   Google Scholar
• Jorand-Lebrun C, Brondyk B, Lin J et al. Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists. Bioorg. Med. Chem. Lett.17(7), 2080–2085 (2007).
   Google Scholar
• Van Koppen CJ, Zaman GJ, Timmers CM et al. A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor. Naunyn Schmiedebergs Arch. Pharmacol.378(5), 503–514 (2008).
   Google Scholar
• Bonger KM, van den Berg RJ, Knijnenburg AD et al. Discovery of selective luteinizing hormone receptor agonists using the bivalent ligand method. ChemMedChem.4(7), 1189–1195 (2009).
   Google Scholar
• Heitman LH, Narlawar R, de Vries H et al. Substituted terphenyl compounds as the first class of low molecular weight allosteric inhibitors of the luteinizing hormone receptor. J. Med. Chem.52(7), 2036–2042 (2009).
   Google Scholar
• Guo T, Adang AE, Dolle RE et al. Small molecule biaryl FSH receptor agonists. Part 1: lead discovery via encoded combinatorial synthesis. Bioorg. Med. Chem. Lett.14(7), 1713–1716 (2004).
   Google Scholar
• Guo T, Adang AE, Dong G et al. Small molecule biaryl FSH receptor agonists. Part 2: lead optimization via parallel synthesis. Bioorg. Med. Chem. Lett.14(7), 1717–1720 (2004).
   Google Scholar
• Yanofsky SD, Shen ES, Holden F et al. Allosteric activation of the follicle-stimulating hormone (FSH) receptor by selective, nonpeptide agonists. J. Biol. Chem.281(19), 13226–13233 (2006).
   PubMed Web of Science ®Google Scholar
• MacLean D, Holden F, Davis AM et al. Agonists of the follicle stimulating hormone receptor from an encoded thiazolidinone library. J. Comb. Chem.6(2), 196–206 (2004).
   PubMedGoogle Scholar
• Wrobel J, Jetter J, Kao W et al. 5-Alkylated thiazolidinones as follicle-stimulating hormone (FSH) receptor agonists. Bioorg. Med. Chem.14(16), 5729–5741 (2006).
   PubMed Web of Science ®Google Scholar
• Pelletier JC, Rogers J, Wrobel J, Perez MC, Shen ES. Preparation of highly substituted γ-lactam follicle stimulating hormone receptor agonists. Bioorg. Med. Chem.13(21), 5986–5995 (2005).
   Google Scholar
• van Straten NC, van Berkel TH, Demont DR et al. Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor. J. Med. Chem.48(6), 1697–1700 (2005).
   Google Scholar
• Wrobel J, Green D, Jetter J et al. Synthesis of (bis)sulfonic acid, (bis)benzamides as follicle-stimulating hormone (FSH) antagonists. Bioorg. Med. Chem.10(3), 639–656 (2002).
   PubMed Web of Science ®Google Scholar
• Arey BJ, Deecher DC, Shen ES et al. Identification and characterization of a selective, nonpeptide follicle-stimulating hormone receptor antagonist. Endocrinology143(10), 3822–3829 (2002).
   PubMed Web of Science ®Google Scholar
• van Straten NC, van Berkel TH, Demont DR et al. Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor. J. Med. Chem.48(6), 1697–1700 (2005).
   Google Scholar
• Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol.3(9), 639–650 (2002).
   PubMed Web of Science ®Google Scholar
• Jaschke H, Neumann S, Moore S et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J. Biol. Chem.281(15), 9841–9844 (2006).
   PubMed Web of Science ®Google Scholar
• Moore S, Jaeschke H, Kleinau G et al. Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure–activity relationships and selective binding patterns. J. Med. Chem.49(13), 3888–3896 (2006).
   PubMed Web of Science ®Google Scholar
• Neumann S, Kleinau G, Costanzi S et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology149(12), 5945–5950 (2008).
   PubMed Web of Science ®Google Scholar
• Inglese J, Auld DS, Jadhav A et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA103(31), 11473–11478 (2006).
   PubMed Web of Science ®Google Scholar
• Titus S, Neumann S, Zheng W et al. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J. Biomol. Screen13(2), 120–127 (2008).
   Google Scholar
• Neumann S, Huang W, Titus S et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc. Natl Acad. Sci. USA106(30), 12471–12476 (2009).
   PubMed Web of Science ®Google Scholar